Memantine and reduced time with dyskinesia in Parkinson's Disease.
(2015) In Acta Neurologica Scandinavica- Abstract
- The partial glutamate antagonist amantadine is currently used in clinical practice, to reduce dyskinesia developing as a side-effect of levodopa treatment in patients suffering from Parkinson's disease (PD). This study was aimed at evaluating the antidyskinetic effect of another glutamate antagonist, memantine.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7845005
- author
- Wictorin, Klas LU and Widner, Håkan LU
- organization
- publishing date
- 2015-08-03
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Neurologica Scandinavica
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:26234336
- scopus:84939216978
- wos:000373774300005
- pmid:26234336
- ISSN
- 1600-0404
- DOI
- 10.1111/ane.12468
- language
- English
- LU publication?
- yes
- id
- c53b7c98-faff-4e7d-97fe-05c16a886a4b (old id 7845005)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26234336?dopt=Abstract
- date added to LUP
- 2016-04-01 14:12:25
- date last changed
- 2022-05-15 17:22:21
@article{c53b7c98-faff-4e7d-97fe-05c16a886a4b,
abstract = {{The partial glutamate antagonist amantadine is currently used in clinical practice, to reduce dyskinesia developing as a side-effect of levodopa treatment in patients suffering from Parkinson's disease (PD). This study was aimed at evaluating the antidyskinetic effect of another glutamate antagonist, memantine.}},
author = {{Wictorin, Klas and Widner, Håkan}},
issn = {{1600-0404}},
language = {{eng}},
month = {{08}},
publisher = {{Wiley-Blackwell}},
series = {{Acta Neurologica Scandinavica}},
title = {{Memantine and reduced time with dyskinesia in Parkinson's Disease.}},
url = {{http://dx.doi.org/10.1111/ane.12468}},
doi = {{10.1111/ane.12468}},
year = {{2015}},
}